Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair
2026年9月10日 更新者:Intuitive Surgical
A Prospective, Multicenter Clinical Investigation of the Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair (MVr)
This study aims to test the safety and effectiveness of Force Feedback instruments used during robotic-assisted mitral valve repair with the da Vinci Surgical System, Model IS5000 (dV5).
研究概览
研究类型
介入性
注册 (估计的)
30
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Manish Bharara
- 邮箱:manish.bharara@intusurg.com
研究联系人备份
- 姓名:Jennifer McCrea
- 电话号码:303-956-0363
- 邮箱:jennifer.mccrea@intusurg.com
学习地点
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- 招聘中
- Emory University
-
接触:
- Clinical Study Coordinator
- 邮箱:OCR@Emory.edu
-
首席研究员:
- Douglas Murphy, MD
-
-
New York
-
New York、New York、美国、10016
- 招聘中
- NYU Langone Health
-
接触:
- Jackie Bott, RN
- 电话号码:212-263-2268
- 邮箱:Jacqueline.Bott@nyulangone.org
-
首席研究员:
- Didier Loulmet, MD
-
副研究员:
- Eugene Grossi, MD
-
-
Washington
-
Spokane、Washington、美国、99204
- 招聘中
- Providence Sacred Heart Medical Center
-
接触:
- Lauren Study Coordinator
- 电话号码:509-474-4345
- 邮箱:lauren.wilcox@providence.org
-
首席研究员:
- Justin Reeves, MD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age ≥22 years.
- Subjects with mitral regurgitation (MR) resulting from primary (degenerative) etiology with normal ventricular function (left ventricular function > 40%) provided that annuloplasty or ventricular repair is feasible robotically.
- Subjects with moderate-severe (Grade 3) or severe (Grade 4) mitral regurgitation (MR) confirmed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) within 60 days of surgery or evaluation for surgery.
- Subjects with low-moderate operative risk (Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score of <4%).
- Subjects that are able to provide written informed consent using the study informed consent form prior to the study.
- Subjects that are willing to comply with protocol-specified follow-up visits.
- Subjects must be candidates for minimally invasive surgery (no contraindications to robotic approach). Based on the study Investigator's clinical judgement, the Subject is deemed suitable to undergo multiport robotic-assisted surgery for mitral valve repair.
Exclusion Criteria:
PREOPERATIVE EXCLUSION CRITERIA:
- Subjects with symptomatic mitral regurgitation determined to be at prohibitive risk for mitral valve surgery.
- Subjects with previous mitral valve surgery, transcatheter repair, or annuloplasty.
- Subjects with prior cardiac surgery (endoscopic, open, or robotic) or ipsilateral thoracic surgery (open, endoscopic, or robotic).
- Subjects with planned emergent procedure (e.g., cardiogenic shock, acute decompensation requiring immediate surgery).
- Subjects requiring surgery with multiple stages (i.e., mitral repair cannot be completed in a single procedure).
- Subject with planned major concomitant surgery for a different medical condition (e.g., coronary artery bypass, cancer resection unrelated to mitral regurgitation).
- Subjects with non-reparable anatomy.
- Subjects with severe pulmonary hypertension (systolic Pulmonary Artery Pressure >70 mmHg).
- Subjects with severe renal insufficiency (estimated Glomerular Filtration Rate <30 mL/min/1.73m²) or liver failure (Child-Pugh C).
- Subjects with active infection.
- Subjects with contraindication to anesthesia/surgery (e.g., severe frailty, uncorrectable coagulopathy).
- Subjects with any past or ongoing condition, or personal circumstance, that in the Investigator's judgment places the Subject at high surgical risk, deems them unsuitable for mitral valve repair, or might interfere with study participation or data collection (e.g., severe chronic obstructive pulmonary disease, uncontrolled diabetes, immunocompromised state, non-compliance).
- Subjects with severe aortic/tricuspid valve disease requiring concurrent open surgery.
- Subjects who are pregnant, suspected pregnancy, or breastfeeding.
- Subjects currently participating in another investigational drug/device study or participation in a significant-risk investigational device study within the past 6 months.
- Subject with inability to complete follow-up (e.g., geographic inaccessibility, dementia).
- Subjects who belong to a vulnerable population (e.g., prisoners, cognitively impaired individuals unable to consent).
INTRAOPERATIVE EXCLUSION CRITERIA:
- Subject with hemodynamic or respiratory instability that precludes the Investigator from performing the Robotic Assisted Surgery (RAS).
- Subject in whom inadequate visualization makes a minimally invasive approach not feasible, as determined by the Investigator assessment prior to docking the robot.
- Subject with adhesions, scarring, and disease status in the body which, in the opinion of the investigator, limits the ability to perform the minimally invasive procedure.
- Subject has any other condition that, in the judgment of the Investigator, might interfere with the collection of complete quality data.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Mitral valve repair including the use of force feedback instruments
Patients with moderate-severe or severe mitral regurgitation resulting from primary (degenerative) etiology who are candidates for robotic-assisted mitral valve repair.
|
Robotic-assisted mitral valve repair including the use of Force Feedback instruments
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of major adverse events
大体时间:30 days postoperative
|
The primary safety endpoint will be evaluated by the incidence of major (Clavien-Dindo Grade III or higher) adverse events related to the use of Force Feedback instruments during robotic-assisted mitral valve repair.
|
30 days postoperative
|
|
Residual Mitral Regurgitation Grade on a Transthoracic Echocardiogram (TTE)
大体时间:Postoperative Day 2-7
|
The primary effectiveness endpoint will be evaluated as residual mitral regurgitation of moderate (Grade 2) or less measured by an echocardiogram after robotic-assisted mitral valve repair.
|
Postoperative Day 2-7
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年7月6日
初级完成 (估计的)
2026年12月31日
研究完成 (估计的)
2027年6月1日
研究注册日期
首次提交
2026年6月10日
首先提交符合 QC 标准的
2026年6月15日
首次发布 (实际的)
2026年6月18日
研究记录更新
最后更新发布 (实际的)
2026年9月14日
上次提交的符合 QC 标准的更新
2026年9月10日
最后验证
2026年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.